Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 401–500 of 1,000
Molecular mechanisms and animal models of spinal muscular atrophy
Edens, B. M., Ajroud‐Driss, S., Ma, L., & Ma, Y. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.07.024 · Cited by 61
Probing disorders of the nervous system using reprogramming approaches
Ichida, J. K., & Kiskinis, E. (2015) · The EMBO Journal · doi:10.15252/embj.201591267 · Cited by 50
“The first “wave” of disease modeling studies focused on generating patient-specific human neurons and confirming previously described pathologies (Dimos et al , 2008; Ebert et al , 2009; Marchetto et al , 2010; Brennand et al , 2011; Seibler et al , 2011; Bilican et al , 2012; Israel et al , 2012).”
Forward engineering neuronal diversity using direct reprogramming
Tsunemoto, R. K., Eade, K., Blanchard, J., & Baldwin, K. K. (2015) · The EMBO Journal · doi:10.15252/embj.201591402 · Cited by 52
“Neurons generated from iPSCs have been used to model loss of function monogenic diseases (Ebert et al, 2009; Lee et al, 2009; Marchetto et al, 2010), as well as, more complex disorders such as schizophrenia (Brennand et al, 2011).”
Species-specific developmental timing is maintained by pluripotent stem cells ex utero
Barry, C., Schmitz, M. T., Jiang, P., Schwartz, M. P., Duffin, B. M., Swanson, S. A., Bacher, R. L., Bolin, J. M., Elwell, A. L., McIntosh, B. E., et al. (2017) · Developmental Biology · doi:10.1016/j.ydbio.2017.02.002 · Cited by 57
“A central challenge for the human embryonic stem (ES) cell and induced pluripotent stem (iPS) cell field is that differentiation rates reflect a species with a nine month gestation period, with protocols often requiring several months (Shi et al., 2012b; Ebert et al., 2009; Espuny-Camacho et al., 2013; Krencik et al.,…”
Self-citationAn integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients
Phatnani, H. P., Kwan, J. Y., Sareen, D., Broach, J. R., Simmons, Z., Arcila-Londono, X., Lee, E. B., Deerlin, V. M. V., Shneider, N. A., Fraenkel, E., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103221 · Cited by 58
Ponnusamy, M. P., Deb, S., Dey, P., Chakraborty, S., Rachagani, S., Senapati, S., & Batra, S. K. (2009) · Stem Cells · doi:10.1002/stem.237 · Cited by 58
Freund, C. M. A. H., Davis, R. P., Gkatzis, K., Oostwaard, D. W., & Mummery, C. L. (2010) · PubMed Central · Cited by 65
Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells
Tanaka, A., Yuasa, S., Node, K., & Fukuda, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818894 · Cited by 54
Hargus, G., Ehrlich, M., Hallmann, A.-L., & Kuhlmann, T. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1222-6 · Cited by 60
“Some of the observed neuronal disease phenotypes could be rescued by the application of valproic acid and tobramycin to SMA-iPS cells [62], which increased the level of SMN protein in the context of SMA [22, 190], further indicating that SMAiPS cells may constitute a suitable cell population for in vitro drug testing…”
BackgroundFattahi, F., Asgari, S., Pournasr, B., Seifinejad, A., Totonchi, M., Taei, A., Aghdami, N., Salekdeh, G. H., & Baharvand, H. (2012) · Molecular Biotechnology · doi:10.1007/s12033-012-9635-3 · Cited by 55
Modelling Human Disease with Pluripotent Stem Cells
Siller, R., Greenhough, S., Park, I., & Sullivan, G. J. (2013) · Current Gene Therapy · doi:10.2174/1566523211313020004 · Cited by 60
“colleagues derived iPSCs from a SMA patient and demonstrated that these could be differentiated to both neurons and astrocytes [33].”
BackgroundCOPI transport complexes bind to specific RNAs in neuronal cells
Todd, A. G., Lin, H., Ebert, A. D., Liu, Y., & Androphy, E. J. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds480 · Cited by 52
“Formaldehyde-cross-linked iPSC-derived motor neuronal cultures (50) were processed for FLRIP and RNA extraction as described for NSC34 cells above.”
MethodSelf-citationNew perspectives on the mechanisms establishing the dorsal-ventral axis of the spinal cord
Andrews, M. G., Kong, J. H., Novitch, B. G., & Butler, S. J. (2018) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2018.12.010 · Cited by 61
“, 2016) and spinal muscular atrophy (SMA) (Ebert et al., 2009), revealing for example, changes in the excitability state of MNs as either a potential cause or immediate outcome of these diseases (Wainger et al.”
BackgroundSynaptotagmin 13 is neuroprotective across motor neuron diseases
Nizzardo, M., Taiana, M. M., Rizzo, F., Benitez, J. A., Nijssen, J., Allodi, I., Melzi, V., Bresolin, N., Comi, G. P., Hedlund, E., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02133-x · Cited by 58
Small Molecules that Promote Self-Renewal of Stem Cells and Somatic Cell Reprogramming
Chen, G., Guo, Y., Li, C., Li, S., & Wan, X. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-09965-w · Cited by 57
Steward, M., Sridhar, A., & Meyer, J. S. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_302 · Cited by 66
“Utilizing hiPSCs derived from an SMA patient, it was demonstrated that these cells exhibited a reduced ability to differentiate into motor neurons, hence recapitulating the disease phenotype (Ebert et al. 2009).”
BackgroundInfluentialDeshmukh, R. S., Kovács, K. A., & Dinnyés, A. (2012) · Stem Cells International · doi:10.1155/2012/379569 · Cited by 53
“Several iPSC lines were derived from spinal muscular atrophy (SMA) [44], schizophrenia [45], familial dysautonomia (FD) [46], and Friedreichs ataxia (FA) patients [47] to study the disease progression.”
BackgroundInduced pluripotent stem cells: A new tool to confront the challenge of neuropsychiatric disorders
Vaccarino, F. M., Stevens, H. E., Kocabas, A., Palejev, D., Szekely, A., Grigorenko, E. L., & Weissman, S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.021 · Cited by 48
“Similarly, iPSCs have been used to investigate the degenerative processes involved in spinal muscular atrophy (SMA), a disorder of lower motor neurons known to result from mutations of the smn genes (Ebert et al., 2009).”
BackgroundSources of retinal pigment epithelium (RPE) for replacement therapy
Lee, E., & MacLaren, R. E. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.171918 · Cited by 53
“perhaps due to more stringent selection of appropriate cell lines. With induced pluripotent stem cells, there are additional concerns about using the oncogenic c-Myc transcription factor, but recent developments have shown that iPS cells can be derived without c-Myc,”
BackgroundUtilizing Regulatory T Cells Against Rheumatoid Arthritis
Haque, M. M., Fino, K. K., Lei, F., Xiong, X., & Song, J. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00209 · Cited by 55
Induced pluripotent stem cells in the study of neurological diseases
Saporta, M., Grs̆ković, M., & Dimos, J. T. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt78 · Cited by 54
“Using this approach, investigators have been able to diff erentiate human pluripotent cells into lineages necessary for model ing neurological diseases, including cholinergic [13,14], glutamatergic [15] and dopaminer gic neurons [16,17], astrocytes [13], oligodendrocytes [18] and Schwann cells [19,20].”
BackgroundMethodDuc, P., Vignes, M., Hugon, G., Sebban, A., Carnac, G., Malyshev, E., Charlot, B., & Rage, F. (2021) · Lab on a Chip · doi:10.1039/d1lc00497b · Cited by 61
Accelerating progress in induced pluripotent stem cell research for neurological diseases
Ito, D., Okano, H., & Suzuki, N. (2012) · Annals of Neurology · doi:10.1002/ana.23596 · Cited by 58
“Recapitulation of the phenotype in disease-specific iPSCs was first reported by Ebert et al using iPSCs derived from a spinal muscular atrophy (SMA) patient.(23) They found that expression of the survival motor neuron (SMN) protein is reduced in iPSCs derived from patients with SMA (which involves deletion of the SMN1…”
BackgroundHigh-Throughput Screening in Primary Neurons
Sharma, P., Ando, D. M., Daub, A. C., Kaye, J., & Finkbeiner, S. M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-391856-7.00041-x · Cited by 50
Stem Cells and Their Derivatives: A Renaissance in Cardiovascular Translational Research
Kattman, S. J., Koonce, C. H., Swanson, B. J., & Anson, B. D. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9235-1 · Cited by 50
“For example, iPS cell models have been established for spinal muscular atrophy [48], familial dysautonomia [49], Faconi and Sickle Cell Anemia [50, 51], Amyotrophic Lateral Sclerosis [52], and Parkinson’s Disease [53].”
BackgroundComparison of different protocols for neural differentiation of human induced pluripotent stem cells
Salimi, A., Nadri, S., Ghollasi, M., Khajeh, K., & Soleimani, M. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3020-1 · Cited by 52
“After exposure to induction media, qPCR analysis indicated that in induction medium 3 neural specific genes including b-tubulin III (neuronal marker), Nestin (neural stem cell marker), NSE (early neuroectoderm marker), MAP-2 (neuronal marker), Olig2 (oligodendrocyte marker) and BDNF (neurogenesis marker) were expresse…”
InfluentialEvolution of induced pluripotent stem cell technology
Zhou, H., & Ding, S. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328339f2ee · Cited by 51
A human-on-a-chip approach to tackling rare diseases
de Mello, C. P. P., Rumsey, J. W., Slaughter, V. L., & Hickman, J. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.08.001 · Cited by 53
Sabitha, K. R., Shetty, A. K., & Upadhya, D. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.025 · Cited by 60
“Reduced dendritic and axonal length with increased selective motor neuron death, a defect mimicking disease phenotype has been recapitulated in motor neurons generated SMA-iPSCs (Ebert et al., 2009; Chang et al., 2011; Ohuchi et al., 2016; Son et al., 2019).”
BackgroundMethodInfluentialHigh-content screening of primary neurons: ready for prime time
Daub, A. C., Sharma, P., & Finkbeiner, S. M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.10.002 · Cited by 58
Lamas, N. J., Johnson-Kerner, B., Roybon, L., Kim, Y. A., Garcia-Diaz, A., Wichterle, H., & Henderson, C. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110324 · Cited by 46
Soares, F. A. C., Chandra, A., Thomas, R. J., Pedersen, R. A., Vallier, L., & Williams, D. J. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2013.12.009 · Cited by 47
“Cellular morphology, pluripotency gene expression and differentiation into the three germ layers have been used compare the outcomes of manual and automated processes.”
MethodBack to the future: how human induced pluripotent stem cells will transform regenerative medicine
Svendsen, C. N. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt379 · Cited by 54
“In certain cases (especially childhood disorders) the cells recapitulate the damage that was seen in the patients – but now they are in a dish (16).”
BackgroundSelf-citationModeling Keratoconus Using Induced Pluripotent Stem Cells
Joseph, R., Srivastava, O. P., & Pfister, R. R. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19105 · Cited by 48
Hosokawa, Y., Hanafusa, T., & Imagawa, A. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13091 · Cited by 49
Generation of induced pluripotent stem cells from human β-thalassemia fibroblast cells
Wang, Y., Jiang, Y., Liu, S., Sun, X., & Gao, S. (2009) · Cell Research · doi:10.1038/cr.2009.100 · Cited by 46
Saitta, B., Passarini, J. D., Sareen, D., Ornelas, L., Sahabian, A., Argade, S., Krakow, D., Cohn, D. H., Svendsen, C. N., & Rimoin, D. L. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0014 · Cited by 53
“The iPSC technology that replicates human disease in the culture dish [17] has already been used to model phenotypes of several disorders [18], including ALS [19,20], muscular dystrophy, Huntington’s disease [21], Parkinson’s disease [22], spinal muscular atrophy [23], Marfan syndrome [24], and osteogenesis imperfecta…”
Self-citationVelasco, I., Salazar, P., Giorgetti, A., Ramos–Mejía, V., Castaño, J., Romero–Moya, D., & Menéndez, P. R. (2014) · Stem Cells · doi:10.1002/stem.1782 · Cited by 53
New Opportunities: Harnessing Induced Pluripotency for Discovery in Diabetes and Metabolism
Teo, A. K. K., Wagers, A. J., & Kulkarni, R. N. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.010 · Cited by 50
Recent Updates on Induced Pluripotent Stem Cells in Hematological Disorders
Wattanapanitch, M. (2019) · Stem Cells International · doi:10.1155/2019/5171032 · Cited by 52
“To date, most studies using disease-specific iPSCs for drug screening have been successfully carried out in neuronal diseases such as Alzheimer’s disease [55], amyotrophic lateral sclerosis [56], motor neuron disease [57], spinal muscular atrophy [58], familial dysautonomia [59], Rett syndrome [60], and Parkinson’s di…”
BackgroundThe evolving field of induced pluripotency: Recent progress and future challenges
Sommer, C., & Mostoslavsky, G. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24155 · Cited by 51
Denis, J. A., Gauthier, M., Rachdi, L., Aubert, S., Giraud-Triboult, K., Poydenot, P., Benchoua, A., Champon, B., Maury, Y., Baldeschi, C., et al. (2013) · Journal of Cell Science · doi:10.1242/jcs.116285 · Cited by 62
“…such as Rett syndrome, familial dysautonomia disorder and spinal muscular atrophy, have been studied following the generation of hiPSCs from patients, and a defective neuronal phenotype associated with the expression of the mutant gene (Ebert et al., 2009; Kim et al., 2011; Lee et al., 2009).”
InfluentialInduced human pluripotent stem cells: promises and open questions
Rolletschek, A., & Wobus, A. M. (2009) · Biological Chemistry · doi:10.1515/bc.2009.103 · Cited by 52
Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types
Engle, S. J., & Vincent, F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.529156 · Cited by 57
Controlling the Stem Cell Compartment and Regeneration In Vivo: The Role of Pluripotency Pathways
Greenow, K. R., & Clarke, A. R. (2012) · Physiological Reviews · doi:10.1152/physrev.00040.2010 · Cited by 51
Leng, L., Tan, Y., Gong, F., Hu, L., Ouyang, Q., Zhao, Y. D., Lu, G., & Lin, G. (2015) · Human Reproduction · doi:10.1093/humrep/deu358 · Cited by 48
“, 2010), spinal muscular atrophy (Ebert et al., 2009), Angelman syndrome (Chamberlain et al.”
BackgroundRegenerative strategies for kidney engineering
Montserrat, N., Garreta, E., & Belmonte, J. C. I. (2016) · FEBS Journal · doi:10.1111/febs.13704 · Cited by 47
Barral, S., & Kurian, M. A. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00078 · Cited by 44
“Spinal muscular atrophy SMN1 Neurons (motor neurons, forebrain neurons, sensory neurons) Astrocytes Ebert et al. (2009), Chang et al. (2011), McGivern et al. (2013), Schwab and Ebert (2014), Boza-Morán et al. (2015), Demestre et al. (2015), Liu et al. (2015), Ng et al. (2015), Fuller et al. (2016),…”
Nanotopography regulates motor neuron differentiation of human pluripotent stem cells
Chen, W., Han, S., Qian, W., Weng, S., Yang, H., Sun, Y., Villa-Diaz, L. G., Krebsbach, P. H., & Fu, J. (2018) · Nanoscale · doi:10.1039/c7nr05430k · Cited by 45
Modeling Protein Aggregation and the Heat Shock Response in ALS iPSC-Derived Motor Neurons
Seminary, E. R., Sison, S. L., & Ebert, A. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00086 · Cited by 49
“For these studies, one SOD1 (N139K) line (Hosoyama et al., 2014), three C9orf72 lines (Sareen et al., 2013), one TDP-43 (M337V) line (Bilican et al., 2012), and three control lines (Ebert et al., 2009;McGivern et al., 2013; Riedel et al., 2014) were used.”
BackgroundSelf-citationHuman stem cell models to study host–virus interactions in the central nervous system
Harschnitz, O., & Studer, L. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-020-00474-y · Cited by 47
Nizzardo, M., Simone, C., Dametti, S., Salani, S., Ulzi, G., Pagliarani, S., Rizzo, F., Frattini, E., Pagani, F., Bresolin, N., et al. (2015) · Scientific Reports · doi:10.1038/srep11746 · Cited by 48
Reprogramming after Chromosome Transfer into Mouse Blastomeres
Egli, D. M., Sandler, V. M., Shinohara, M. L., Cantor, H., & Eggan, K. C. (2009) · Current Biology · doi:10.1016/j.cub.2009.06.065 · Cited by 43
“This approach, if successful with human cells, would allow the production of human stem cell lines from individual patients for personalized medicine or in vitro modeling of their condition [3–5].”
In vitro neurogenesis: development and functional implications of iPSC technology
Compagnucci, C., Nizzardo, M., Corti, S. P., Zanni, G., & Bertini, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1511-1 · Cited by 50
Winkler, T., Cantilena, A. R., Métais, J., Xu, X., Nguyen, A., Borate, B. R., Antosiewicz‐Bourget, J., Wolfsberg, T. G., Thomson, J. A., & Dunbar, C. E. (2010) · Stem Cells · doi:10.1002/stem.322 · Cited by 48
Self-citationCastiglioni, V., Onorati, M., Rochon, C., & Cattaneo, E. F. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.032 · Cited by 49
Translational Prospects for Human Induced Pluripotent Stem Cells
CSETE, M. E. (2010) · Regenerative Medicine · doi:10.2217/rme.10.39 · Cited by 46
Begum, A. N., Guoynes, C. D., Cho, J., Hao, J., Lutfy, K., & Hong, Y. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.10.014 · Cited by 47
“…nuclear antigen; SHH, sonic ity Lab, College of Veterinary ast Second Street, Pomona, CA ss article under the CC BY-NC-ND lic muscular atrophy (Ebert et al., 2009) and familial dysautonomia (Lee et al., 2009), as well as inherited and sporadic forms of various human neurodegenerative…”
BackgroundWhen rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease
Vera, E., & Studer, L. (2015) · Development · doi:10.1242/dev.120667 · Cited by 43
“There has been considerable success in modeling early developmental disorders of the nervous system such as spinal muscular atrophy, familial dysautonomia or primary herpes simplex encephalitis (Ebert et al., 2009; Lee et al., 2009; Lafaille et al., 2012), among many others.”
BackgroundInduced pluripotent stem cells for modeling neurological disorders
Russo, F. B., Cugola, F. R., Fernandes, I. R., Pignatari, G. C., & Beltrão-Braga, P. C. B. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i4.209 · Cited by 48
Modeling rare diseases with induced pluripotent stem cell technology
Anderson, R. H., & Francis, K. R. (2018) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2018.01.001 · Cited by 53
What can pluripotent stem cells teach us about neurodegenerative diseases?
Wichterle, H., & Przedborski, S. (2010) · Nature Neuroscience · doi:10.1038/nn.2577 · Cited by 50
“Pluripotent stem cells have already been derived from individuals carrying inherited defect”
BackgroundInduced neural stem cells: Methods of reprogramming and potential therapeutic applications
Ruggieri, M., Riboldi, G. M., Brajkovic, S., Bucchia, M., Bresolin, N., Comi, G. P., & Corti, S. P. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.001 · Cited by 47
“…diseases, such as Parkinson’s disease (Park al., 2008; Soldner et al., 2011), amyotrophic lateral sclerosis imos et al., 2008), spinal muscular atrophy (Ebert et al., 2009), zheimer’s disease (Israel et al., 2012), Huntington’s disease (Park al., 2008), and schizophrenia (Brennand et al., 2011).”
BackgroundStem Cells in the Nervous System
Maldonado‐Soto, A. R., Oakley, D. H., Wichterle, H., Stein, J. M., Doetsch, F. K., & Henderson, C. E. (2014) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000000111 · Cited by 43
“Furthermore, spinal muscular atrophy iPSmotor neurons (MNs) are less abundant in culture than control iPS-MNs after 6 wks of differentiation, despite being present at similar levels 2 wks before this time point.(52) The numbers of motor neurons can be increased either by genetic correction of the deficit(61) or by blo…”
BackgroundRizzo, F., Nizzardo, M., Vashisht, S., Molteni, E., Melzi, V., Taiana, M. M., Salani, S., Santonicola, P., Schiavi, E. D., Bucchia, M., et al. (2019) · Brain · doi:10.1093/brain/awy330 · Cited by 47
Differentiating human stem cells into neurons and glial cells for neural repair
Selvaraj, V., Jiang, P., Chechneva, O., Lo, U., & Deng, W. (2011) · Frontiers in bioscience · doi:10.2741/3916 · Cited by 43
Derivation of Ethnically Diverse Human Induced Pluripotent Stem Cell Lines
Chang, E. A., Tomov, M. L., Suhr, S. T., Luo, J., Olmsted, Z. T., Paluh, J. L., & Cibelli, J. B. (2015) · Scientific Reports · doi:10.1038/srep15234 · Cited by 41
Patient-Specific Pluripotent Stem Cells in Neurological Diseases
Durnaoglu, S., Genç, Ş., & Genç, K. (2011) · Stem Cells International · doi:10.4061/2011/212487 · Cited by 47
“it showed that SMA-iPSCs-derived neural cells undergo selective neuronal death, which could be reversed by adding the compounds known to raise the production of SMN protein [91].”
BackgroundInfluentialConcise Review: A High-Content Screening Approach to Stem Cell Research and Drug Discovery
Xia, X., & Wong, S. T. C. (2012) · Stem Cells · doi:10.1002/stem.1168 · Cited by 58
Induced Pluripotent Stem Cell Potential in Medicine, Specifically Focused on Reproductive Medicine
Botman, O., & Wyns, C. (2014) · Frontiers in Surgery · doi:10.3389/fsurg.2014.00005 · Cited by 42
“Spinal muscular atrophy (99) Fibroblast Y”
The potential of induced pluripotent stem cells as a translational model for neurotoxicological risk
Kumar, K. K., Aboud, A. A., & Bowman, A. B. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.02.005 · Cited by 44
“…IH -PA Author M anuscript 4.2 Inconsistency and low-efficiency of neuronal differentiation methods hiPSCs are in many aspects similar to hESCs and can be differentiated in culture into multiple cell types including neurons (Chamberlain et al., 2008; Dimos et al., 2008; Ebert et al., 2009).”
BackgroundInfluentialiPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery
Zhang, R., Zhang, L., & Xie, X. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.21 · Cited by 46
Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia
Watson, L. M., Wong, M. M. K., & Becker, E. B. E. (2015) · Open Biology · doi:10.1098/rsob.150056 · Cited by 44
“The potential of iPSCs to differentiate into any cell type of the body, offering the opportunity to study diseases of the CNS without the need for invasive surgical techniques, has been widely exploited, notably in the derivation of neurons from patients with a variety of neurodegenerative conditions [23–26].”
BackgroundTherapeutic genome editing in cardiovascular diseases
Nishiga, M., Qi, L. S., & Wu, J. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.003 · Cited by 44
Deriving Dorsal Spinal Sensory Interneurons from Human Pluripotent Stem Cells
Gupta, S. K., Sivalingam, D., Hain, S., Makkar, C., Sosa, E., Clark, A. T., & Butler, S. J. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.12.012 · Cited by 44
“, 2016) and spinal muscular atrophy (Ebert et al., 2009), as well permitting cellular replacement in injury models (Harper et al.”
BackgroundApplications of induced pluripotent stem cells in studying the neurodegenerative diseases
Wan, W., Cao, L., Kalionis, B., Xia, S., & Tai, X. (2015) · Stem Cells International · doi:10.1155/2015/382530 · Cited by 40
“reported the generation of iPSCs from skin fibroblast samples taken from a child with SMA and subsequently the iPSCs were differentiated into MNs, which expressed particular defects when compared toMNs from the child’s unaffected mother [103].”
BackgroundInfluentialLi, Y., Balasubramanian, U., Cohen, D. A., Zhang, P.-W., Mosmiller, E., Sattler, R., Maragakis, N. J., & Rothstein, J. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118266 · Cited by 45
“Remarkably, these cells can be differentiated to the type of cells which are critical for disease development, such as motor neurons from ALS-iPSCs [18,24–26], and they have been successfully used in disease modeling in neurological diseases like ALS, spinal muscular atrophy and familial dysautonomia [20,21,27].”
BackgroundKumar, P., & Chan, W. (2011) · Current Gene Therapy · doi:10.2174/156652311794940782 · Cited by 45
“The generation of patient-specific iPSCs from skin fibroblasts from a child with spinal muscular atrophy was also possible [140].”
BackgroundRoadblocks en route to the clinical application of induced pluripotent stem cells
Lowry, W. E., & Quan, W. L. (2010) · Journal of Cell Science · doi:10.1242/jcs.054304 · Cited by 43
“Currently, there is great excitement about the use of hiPSCs to study human disease and tissue development in vitro (Dimos et al., 2008; Ebert et al., 2008; Park et al., 2008a).”
BackgroundEmerging Methods for Preparing iPS Cells
Miyazaki, S., Yamamoto, H., Miyoshi, N., Takahashi, H., Suzuki, Y., Haraguchi, N., Ishii, H., Doki, Y., & Mori, M. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys108 · Cited by 45
“Oct3/4, Sox2, Nanog and lin28 Human Fibroblasts (40)”
BackgroundKaus, A. S., & Sareen, D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00448 · Cited by 45
“Systems biology approaches utilizing large scale genomics, transcriptomics and proteomics will help identify novel targets of MNDs such as ALS and SMA compared to iPSC derived MNs from control patients.”
MethodInfluentialiPSCs-Based Neural 3D Systems: A Multidimensional Approach for Disease Modeling and Drug Discovery
Costamagna, G., Andreoli, L., Corti, S. P., & Faravelli, I. (2019) · Cells · doi:10.3390/cells8111438 · Cited by 43
“modeled using iPSCs and their pathological features thoroughly described: hyperexcitability, altered axonal transport and increased apoptosis in spinal muscular atrophy (SMA) neurons [14,15]; elevated lysosomal activity and higher response to glutamate in iPSC-derived neurons from Huntington disease patients [16–18];…”
BackgroundBoza-Moran, M.-G., Martínez‐Hernández, R., Bernal, S., Wanisch, K., Also‐Rallo, E., Heron, A. L., Alías, L., Denis, C., Girard, M., Yee, J., et al. (2015) · Scientific Reports · doi:10.1038/srep11696 · Cited by 44
Thomson, S. R., Wishart, T. M., Patani, R., Chandran, S., & Gillingwater, T. H. (2011) · Journal of Anatomy · doi:10.1111/j.1469-7580.2011.01459.x · Cited by 46
“…and structural disturbance of the NMJ in ALS and ALS-like conditions has been presented from a range of other animal models, including mice, dogs, zebrafish, Caenorhabditis elegans and Drosophila (Rich et al. 2002; Ferri et al. 2003; Feiguin et al. 2009; Wang et al. 2009; Ramesh et al. 2010).”
BackgroundReprogramming Therapeutics: iPS Cell Prospects for Neurodegenerative Disease
Abeliovich, A., & Doege, C. A. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.024 · Cited by 43
Induced Pluripotent Stem Cells: Emerging Techniques for Nuclear Reprogramming
Han, J. W., & Yoon, Y. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3814 · Cited by 51
“OK Dermal papilla cells (179) OK NSCs (54) OK/O NSCs (71) Lentiviral vectors OSKM/OSNL Fibroblasts Large T (104) OSNL Fibroblasts from patients (33) OSNL Cord blood cells (47) Inducible lentiviral vectors (tet) OSKM/OKM/OSK Melanocytes (181) OSKM Blood cell, T cell/PB–MNC (96) Inducible lentiviral vectors (tet), singl…”
BackgroundInducible pluripotent stem cells: not quite ready for prime time?
Robbins, R. D., Prasain, N., Maier, B. F., Yöder, M. C., & Mirmira, R. G. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283337196 · Cited by 43
Thomson, S. R., Nahon, J. E., Mutsaers, C. A., Thomson, D., Hamilton, G., Parson, S. H., & Gillingwater, T. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052605 · Cited by 45
“recreate motor units from motor neuron disease patients in a dish [40,41].”
BackgroundEvolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
“…pathology focused on diseases characterized by both the loss of function of a single gene product and rapid disease progression in early childhood (Ebert et al., 2009; Lee et al., 2009; Marchetto et al., 2010), many groups have recently extended these studies to complex genetic psychiatric…”
BackgroundMethodAssays for the Identification and Prioritization of Drug Candidates for Spinal Muscular Atrophy
Cherry, J. J., Kobayashi, D. T., Lynes, M. M., Naryshkin, N. N., Tiziano, F. D., Zaworski, P. G., Rubin, L. L., & Jarecki, J. (2014) · Assay and Drug Development Technologies · doi:10.1089/adt.2014.587 · Cited by 43
“This allows for the production of iPS cells from SMA patients 95,198–202 and also facilitates the building of iPS cell collections that represent a range of patient genotypes and disease severities (L. Rubin, Harvard University, pers. comm.).”
Cell-Based Screening: Extracting Meaning from Complex Data
Finkbeiner, S., Frumkin, M., & Kassner, P. D. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.023 · Cited by 39
“, 2013), spinal muscular atrophy (Ebert et al., 2009), Parkinson’s disease (Cooper et al.”
Modeling Neurological Diseases Using Patient-Derived Induced Pluripotent Stem Cells
Juopperi, T. A., Song, H., & Ming, G.-L. (2011) · Future Neurology · doi:10.2217/fnl.11.14 · Cited by 39
Miho, M., Harris, A. W., Kingham, B. F., Lumpkin, C. J., Opdenaker, L. M., McCahan, S. M., Wang, W., & Butchbach, M. E. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106818 · Cited by 47
“observed in MNs differentiated from induced pluripotent stem cell (iPSC) lines derived from human SMA fibroblasts [96–99].”
BackgroundInduced pluripotent stem cells: A new technology to study human diseases
Vitale, A. M., Wolvetang, E. J., & Mackay‐Sim, A. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.03.013 · Cited by 41
“…motor neurons. iPS cells established from a patient suffering SMA (iPS-SMA) maintain the disease phenotype and are capable of differentiation into motor neurons initially, but when compared to those derived from the patient’s unaffected mother, they degenerate with time (Ebert et al., 2009).”
BackgroundPlastin 3 is upregulated in iPSC-derived motoneurons from asymptomatic SMN1-deleted individuals
Heesen, L., Peitz, M., Torres‐Benito, L., Hölker, I., Hupperich, K., Dobrindt, K., Jungverdorben, J., Ritzenhofen, S., Weykopf, B., Eckert, D., et al. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2084-y · Cited by 48
“Previously, a cellular in vitro SMA model was established from a SMA I patient displaying essential features of in vivo SMA pathology such as reduced SMN expression and gem numbers, and impeded MN survival rate [23].”
BackgroundInfluentialImpact of new technologies for cellular screening along the drug value chain
Möller, C., & Slack, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.010 · Cited by 42
Modeling Huntington׳s disease with patient-derived neurons
Mattis, V. B., & Svendsen, C. N. (2015) · Brain Research · doi:10.1016/j.brainres.2015.10.001 · Cited by 42
“The first published hiPSC model of a neurodegenerative disease used fibroblasts from a patient with Spinal Muscular Atrophy and the unaffected carrier parent as a control (Ebert et al., 2009).”
MethodSelf-citationSimon, C. M., Janas, A., Lotti, F., Tapia, J. C., Pellizzoni, L., & Mentis, G. Z. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.087 · Cited by 45
“This is in agreement with previous in vitro and in vivo studies that used stem cell-derived mouse and human MNs (Ebert et al., 2009; Makhortova et al., 2011; Sareen et al., 2012; Ng et al., 2015) as well as selective restoration of SMN in MNs of SMA mice (Gogliotti et al., 2012; Martinez et al.,…”
ResultSimple Derivation of Spinal Motor Neurons from ESCs/iPSCs Using Sendai Virus Vectors
Goto, K., Imamura, K., Komatsu, K., Mitani, K., Aiba, K., Nakatsuji, N., Inoue, M., Kawata, A., Yamashita, H., Takahashi, R., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.007 · Cited by 40
AAV9-mediated delivery of miR-23a reduces disease severity in Smn2B/−SMA model mice
Kaifer, K. A., Villalón, E., O’Brien, B. S., Sison, S. L., Smith, C. E., Simon, M. E., Marquez, J., O’Day, S., Hopkins, A. E., Neff, R., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz142 · Cited by 39
Self-citation
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.